Cyclosporine
Brand name: Restasis
Rank #26 of 500 drugs by total cost
$684.1M
Total Cost
723,620
Total Claims
$684.1M
Total Cost
16,631
Prescribers
$945
Cost per Claim
211,455
Beneficiaries
1,158,686
30-Day Fills
$41K
Avg Cost/Provider
44
Avg Claims/Provider
About Cyclosporine
Cyclosporine (sold as Restasis) was prescribed 723,620 times by 16,631 Medicare Part D providers in 2023, costing the program $684.1M. At $945 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology